Story perspectives

Healthgen Biotech Pioneers Unprofitable IPOs Amid Challenges

10/9/2025

Summary

Story summary

Healthgen Biotech leads China's Initial Public Offering (IPO) reopening, first unprofitable biotech to pass Star Market review.
The Star Market revival lets loss-makers go public; Healthgen seeks funds to scale recombinant-protein production, despite CN¥450 million losses.
Healthgen faces IP (intellectual property) dispute with US-based Ventria Bioscience, hindering commercialization.
The rice-based recombinant human serum albumin (rHSA) must prove scalability and affordability.

1 of 1

Story summary

Healthgen Biotech leads China's Initial Public Offering (IPO) reopening, first unprofitable biotech to pass Star Market review.
The Star Market revival lets loss-makers go public; Healthgen seeks funds to scale recombinant-protein production, despite CN¥450 million losses.
Healthgen faces IP (intellectual property) dispute with US-based Ventria Bioscience, hindering commercialization.
The rice-based recombinant human serum albumin (rHSA) must prove scalability and affordability.